From: Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma
NVP-Bez235 (nM)
Su-DHL2
IC50
27.76
CI 95Â %
19.82–35.56
OCI-Ly3
27.39
22.92–31.86
OCI-Ly10
36.86
30.2–43.47